Abcellera Short Term Debt from 2010 to 2024

ABCL Stock  USD 2.95  0.19  6.88%   
Abcellera Biologics Short Term Debt yearly trend continues to be quite stable with very little volatility. The value of Short Term Debt is projected to decrease to about 4 M. From the period between 2010 and 2024, Abcellera Biologics, Short Term Debt regression line of its data series had standard deviation of  1,323,205 and standard deviation of  1,323,205. View All Fundamentals
 
Short Term Debt  
First Reported
2010-12-31
Previous Quarter
6.2 M
Current Value
M
Quarterly Volatility
1.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Abcellera Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Abcellera Biologics' main balance sheet or income statement drivers, such as Net Interest Income of 44.4 M, Interest Income of 44.4 M or Depreciation And Amortization of 32.4 M, as well as many indicators such as Price To Sales Ratio of 41.25, Dividend Yield of 0.0 or PTB Ratio of 1.36. Abcellera financial statements analysis is a perfect complement when working with Abcellera Biologics Valuation or Volatility modules.
  
Check out the analysis of Abcellera Biologics Correlation against competitors.
For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.

Latest Abcellera Biologics' Short Term Debt Growth Pattern

Below is the plot of the Short Term Debt of Abcellera Biologics over the last few years. It is Abcellera Biologics' Short Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Abcellera Biologics' overall financial position and show how it may be relating to other accounts over time.
Short Term Debt10 Years Trend
Slightly volatile
   Short Term Debt   
       Timeline  

Abcellera Short Term Debt Regression Statistics

Arithmetic Mean3,060,007
Geometric Mean2,807,824
Coefficient Of Variation43.24
Mean Deviation950,241
Median2,531,350
Standard Deviation1,323,205
Sample Variance1.8T
Range5.3M
R-Value0.57
Mean Square Error1.3T
R-Squared0.33
Significance0.03
Slope168,959
Total Sum of Squares24.5T

Abcellera Short Term Debt History

2024M
20236.2 M
20225.6 M
20213.7 M
2020865 K
20192.9 M

About Abcellera Biologics Financial Statements

Abcellera Biologics investors utilize fundamental indicators, such as Short Term Debt, to predict how Abcellera Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Short Term Debt6.2 MM

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Abcellera Biologics is a strong investment it is important to analyze Abcellera Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Abcellera Biologics' future performance. For an informed investment choice regarding Abcellera Stock, refer to the following important reports:
Check out the analysis of Abcellera Biologics Correlation against competitors.
For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.459
Earnings Share
(0.61)
Revenue Per Share
0.112
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.13)
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.